Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Trial Profile

Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Spanlecortemlocel (Primary) ; Tacrolimus (Primary)
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2020 According to a Magenta Therapeutics media release, Sixteen of 18 patients have been enrolled in the Phase 2 trial of MGTA-456 in patients with blood cancers at the University of Minnesota.
    • 16 Apr 2020 According to a Magenta Therapeutics media release, this Phase 2 study in blood cancers expected to complete enrollment in 2020
    • 20 Feb 2020 According to a Magenta Therapeutics media release, John Wagner, M.D., (University of Minnesota) today presented results from this study at the at the Transplant and Cellular Therapy (TCT) Annual Meeting in Orlando, Florida.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top